Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [1] Smart energy: where do we stand and where should we go?
    Kranz, Johann
    Kolbe, Lutz M.
    Koo, Chulmo
    Boudreau, Marie-Claude
    ELECTRONIC MARKETS, 2015, 25 (01) : 7 - 16
  • [2] Smart energy: where do we stand and where should we go?
    Johann Kranz
    Lutz M. Kolbe
    Chulmo Koo
    Marie-Claude Boudreau
    Electronic Markets, 2015, 25 : 7 - 16
  • [3] Tackling the problems of polypharmacy - Where do we stand and where should we go?
    Onder, G.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2015, 48 : 4 - 4
  • [4] Olive oil phenolics: Where do we stand? Where should we go?
    Visioli, Francesco
    JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 2012, 92 (10) : 2017 - 2019
  • [5] Climate change and desertification: Where do we stand, where should we go?
    Verstraete, Michel M.
    Brink, Andreas B.
    Scholes, Robert J.
    Beniston, Martin
    Smith, Mark Stafford
    GLOBAL AND PLANETARY CHANGE, 2008, 64 (3-4) : 105 - 110
  • [6] Uterus transplantation:: where do we stand today and where should we go?
    Brannstrom, Mats
    Wranning, Caiza Almen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 427 - 429
  • [7] Gephyrin: where do we stand, where do we go?
    Fritschy, Jean-Marc
    Harvey, Robert J.
    Schwarz, Guenter
    TRENDS IN NEUROSCIENCES, 2008, 31 (05) : 257 - 264
  • [8] Shift-work research: Where do we stand, where should we go?
    Thomas Kantermann
    Myriam Juda
    Céline Vetter
    Till Roenneberg
    Sleep and Biological Rhythms, 2010, 8 : 95 - 105
  • [9] Standard treatment in anal cancer: where do we stand and where should we go?
    Muirhead, R.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S250 - S250
  • [10] Shift-work research: Where do we stand, where should we go?
    Kantermann, Thomas
    Juda, Myriam
    Vetter, Celine
    Roenneberg, Till
    SLEEP AND BIOLOGICAL RHYTHMS, 2010, 8 (02) : 95 - 105